Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500146 | 0.86 | NR3C1 (0.34) | IDO1AGXTPKMACHEHTR2A | |
| SCHEMBL19859281 | 0.85 | IDO1 (0.41) | IDO1AGXTPKMPRMT5EGFR | |
| SCHEMBL10574366 | 0.82 | IDO1 (0.39) | IDO1AGXTPKMPRMT5EGFR | |
| SCHEMBL15335397 | 0.81 | PTPN1 (0.31) | — | |
| SCHEMBL31145078 | 0.79 | IDO1 (0.40) | IDO1HTR2A | |
| SCHEMBL500010 | 0.79 | — | — | |
| SCHEMBL3795527 | 0.77 | SLC5A1 (0.36) | P2RX7HTR2A | |
| SCHEMBL15335354 | 0.77 | — | — | |
| SCHEMBL23148174 | 0.76 | PYCR1 (0.42) | IDO1AGXTNAAA | |
| SCHEMBL5055153 | 0.76 | IDO1 (0.34) | IDO1AGXTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3424932-B1 | BORONOPHTHALIDES FOR THERAPEUTIC USE | ANACOR PHARMACEUTICALS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210070780-A1 | Boron-Containing Small Molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210000847-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-20200179418-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200046745-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20190330245-A1 | Boron-Containing Small Molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190282594-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190160081-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2007095638-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007078340-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
| US-20060234981-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2006-10-19 | — | — | US | disclosed |
| CN-1829521-A | Hydrolysis resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS INC (US) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006089067-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1638578-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005013892-A9 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS INC (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2005013892-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234981-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | IDO1 352/4885AGXT 2547/4885PKM 4663/4885 |
| US-20190160081-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | IDO1 1994/4885AGXT 4198/4885PKM 4816/4885 |
| US-20190330245-A1 | Boron-Containing Small Molecules | ETF1, POLR1C, DPM1 | IDO1 352/4885AGXT 2547/4885PKM 4663/4885 |
| US-20230008130-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | IDO1 1994/4885AGXT 4198/4885PKM 4816/4885 |
| US-20200046745-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | IDO1 1994/4885AGXT 4198/4885PKM 4816/4885 |
| US-20200179418-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | IDO1 1994/4885AGXT 4198/4885PKM 4816/4885 |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | IDO1 1994/4885AGXT 4198/4885PKM 4816/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | IDO1 352/4885AGXT 2547/4885PKM 4663/4885 |
| US-20210070780-A1 | Boron-Containing Small Molecules | ETF1, POLR1C, DPM1 | IDO1 352/4885AGXT 2547/4885PKM 4663/4885 |
| US-20050054644-A1 | Hydrolytically-resistant boron-containing therapeutics and methods of use | BTD, GAA, GBA3 | IDO1 2697/4885AGXT 317/4885PKM 2388/4885 |
| US-20190282594-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | IDO1 1994/4885AGXT 4198/4885PKM 4816/4885 |
| US-20210000847-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | IDO1 1994/4885AGXT 4198/4885PKM 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.